Effect of oral mexiletine versus quinidine on premature ventricular complexes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.

Original languageEnglish
Pages (from-to)1070-1074
Number of pages5
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume33
Issue number6 II
StatePublished - 1983

Fingerprint

Mexiletine
Quinidine
Ventricular Premature Complexes
Polyvinyl Chloride
Pharmaceutical Preparations
Ambulatory Monitoring

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{4d887838f81d472483db3efd943a8f14,
title = "Effect of oral mexiletine versus quinidine on premature ventricular complexes",
abstract = "We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38{\%}) on quinidine and in 4 of 6 patients (67{\%}) on mexiletine. Two of 8 patients (25{\%}) on quinidine and 4 of 6 patients (67{\%}) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70{\%} during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67{\%}) on quinidine and in 3 of 6 patients (50{\%}) on mexiletine. Four of 8 patients (50{\%}) on quinidine and one of 6 patients (17{\%}) on mexiletine were able to tolerate the drug and have at least 70{\%} reduction of PVCs.",
author = "Esterbrooks, {Dennis J.} and Mohiuddin, {Syed M.} and Aronow, {W. S.}",
year = "1983",
language = "English",
volume = "33",
pages = "1070--1074",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "6 II",

}

TY - JOUR

T1 - Effect of oral mexiletine versus quinidine on premature ventricular complexes

AU - Esterbrooks, Dennis J.

AU - Mohiuddin, Syed M.

AU - Aronow, W. S.

PY - 1983

Y1 - 1983

N2 - We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.

AB - We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.

UR - http://www.scopus.com/inward/record.url?scp=0020620716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020620716&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 1070

EP - 1074

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 6 II

ER -